First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ApexOnco Front Page
Recent articles
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
The company will acquire ImCheck for €350m.
But Perspective sinks again.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
Innovent’s perseverance with a cytokine approach is rewarded with $1.2bn from Takeda.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.